Overview
The marketing authorisation for Doxirobe has not been renewed by the marketing authorisation holder and is now withdrawn.
Authorisation details
| Product details | |
|---|---|
| Name |
Doxirobe
|
| Agency product number |
EMEA/V/C/000044
|
| Active substance |
doxycycline
|
| International non-proprietary name (INN) or common name |
Doxycycline
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01AA02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
16/09/1999
|
| Contact address | |
Product information
01/12/2003 Doxirobe - EMEA/V/C/000044 -
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Treatment of periodontal disease in dogs.
Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.